Empagliflozin's Microcirculatory Effects in Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial
NCT07141355 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2025-08-26
Summary
Despite advancements in treatment, the mortality rate for cardiogenic shock (CS) remains high at around 50%. The EMPULSE-HF trial showed that early introduction of empagliflozin in stabilized patients with acute heart failure led to a composite benefit in mortality, rehospitalization, and quality of life.
Growing evidence suggests that cardiogenic shock isn't just a problem of systemic macrocirculation (blood pressure, cardiac output). It also involves significant abnormalities in the systemic microcirculation. In fact, these microcirculatory parameters have proven to be better predictors of patient outcomes than traditional macrocirculatory measures.
Given its known vasculo-protective effects on the endothelium, empagliflozin may have a beneficial impact on the microcirculation, potentially explaining its positive effects in cardiogenic shock.
This study will explore this hypothesis by analyzing the microcirculation in real-time using the CytoCam-IDF imaging videomicroscope and its MicroTools software. The goal is to gain a deeper understanding of how empagliflozin affects the microcirculation during cardiogenic shock.
Conditions
- Cardiogenic Shock
Interventions
- DIAGNOSTIC_TEST
-
microcirculation using the video microscopy tool.
The study intervention is the assessment of microcirculation using the video microscopy tool. This study's primary purpose is to perform this specific diagnostic procedure-measuring microcirculatory parameters with the CytoCam-IDF device-at two distinct time points: at inclusion (H0) and again 48 hours later (H48). The administration of empagliflozin (or not), which is pa and 48 hours after initiating empagliflozin treatment, microcirculatory data will be collected using a videomicroscope. A camera, roughly the size of a large pen, is placed under the patient's tongue for a few seconds to acquire images of the sublingual microcirculation. The entire image acquisition process takes less than 5 minutes and is unaffected by whether the patient is intubated. Images are then analyzed in real-time by the MicroTools software, which calculates key microcirculatory parameters. All anonymized images are stored on a dedicated, password-protected computer accessible only to the investigators.
Sponsors & Collaborators
-
University Hospital, Strasbourg, France
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SCREENING
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-01
- Primary Completion
- 2027-08-31
- Completion
- 2027-09-30
Countries
- France
Study Locations
More Related Trials
-
Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
NCT03027960 ·Status: COMPLETED ·Phase: PHASE1
-
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
NCT06046612 ·Status: UNKNOWN ·Phase: PHASE4
-
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
NCT04509674 ·Status: COMPLETED ·Phase: PHASE3
-
Empagliflozin in Hypertrophic Cardiomyopathy
NCT05182658 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure
NCT04049045 ·Status: COMPLETED ·Phase: PHASE2
-
The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure
NCT05084235 ·Status: COMPLETED ·Phase: PHASE2
-
A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin
NCT03332212 ·Status: COMPLETED ·Phase: PHASE3
-
Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.
NCT03773822 ·Status: COMPLETED ·Phase: PHASE3
-
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
NCT03271879 ·Status: UNKNOWN ·Phase: PHASE4
-
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
NCT05776043 ·Status: RECRUITING ·Phase: PHASE3
-
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
NCT07038356 ·Status: RECRUITING ·Phase: PHASE3
-
SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
NCT06955260 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction
NCT03198585 ·Status: COMPLETED ·Phase: PHASE2
-
EMPA Acute Heart Failure
NCT03554200 ·Status: TERMINATED ·Phase: PHASE2
-
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
NCT06632561 ·Status: COMPLETED ·Phase: PHASE4
-
Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
NCT03030222 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department
NCT06683053 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
NCT05271162 ·Status: RECRUITING ·Phase: PHASE3
-
" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
NCT05580510 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
NCT05795400 ·Status: COMPLETED ·Phase: NA
-
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
NCT06433050 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.
NCT00050076 ·Status: COMPLETED ·Phase: PHASE2
-
Use of SGLT2i in noHCM With HFpEF
NCT06401343 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction
NCT05778084 ·Status: UNKNOWN ·Phase: PHASE4
-
Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors
NCT05344963 ·Status: COMPLETED